Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tataa Biocenter AB maintains a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The company currently faces 1 pending office action. This 1 action is handled by 1 distinct examiner, reflecting a concentrated scope of active prosecution at this stage. For a practitioner, this suggests that the company's immediate patent strategy is focused on 1 matter rather than a broad array of filings.
The prosecution activity is confined to 1 distinct art unit. JONES, CHRISTINE MICHELLE is identified as the busiest examiner for this portfolio. This examiner is currently managing 1 busiest examiner pending office action. The alignment of 1 pending action with 1 examiner and 1 art unit suggests a focus for the company's current legal interactions with the patent office. This concentration allows for a specific prosecution approach, as the company only needs to navigate the preferences of the assigned examiner in 1 technical division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18594668 | METHODS AND COMPOSITIONS FOR DETECTION OF MUTANT NUCLEIC ACID SEQUENCES | JONES, CHRISTINE MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18594668 | METHODS AND COMPOSITIONS FOR DETECTION OF MUTANT NUCLEIC ACID SEQUENCES | JONES, CHRISTINE MICHELLE | 1682 | §112DP | Non-Final OA | — | Pending | Mar 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTataa Biocenter AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christine Michelle Jones has the most, with 1 of Tataa Biocenter AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
